TCR sequencing (TCR-seq)
Overview
Targeted sequencing of T-cell receptor (typically TCRβ) CDR3 regions to characterize T-cell repertoire diversity, clonality, and tumor-enriched clones.
Used by
- PMID:37202560 — deep TCRβ sequencing (immunoSEQ) on 348 AC-ICAM colon cancer tumor/normal pairs; the ICR signature captured the presence of clonally expanded, tumor-enriched T cell clones and outperformed CMS and MSI classification for prognosis PMID:37202560.
- T-cell receptor β CDR3 deep sequencing via Adaptive Biotechnologies immunoSEQ performed on MET500 metastatic tumors; TCR-β clonality confirmed expansion of dominant T-cell clones in high-MImmScore tumors and validated RNA-seq-based immune scoring PMID:28783718
- TCR β-chain sequencing (Adaptive Biotechnologies immunoSEQ) on tumor DNA from 34 paired pre/on-therapy melanoma biopsies; expanded T-cell clones correlated with neoantigen loss in responders (p=0.03) PMID:29033130
Notes
- TCR-seq complements bulk RNA-seq, WES, and 16S microbiome profiling in the AC-ICAM multi-omics workflow PMID:37202560.
Sources
This page was processed by crosslinker on 2026-04-08. - PMID:28783718
This page was processed by entity-page-writer on 2026-05-15. - PMID:29033130
This page was processed by entity-page-writer on 2026-05-15.